共 50 条
- [1] Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma[J]. BLOOD, 2014, 124 (21)Penebre, ElayneKuplast, Kristy G.Majer, Christina R.Johnston, L. DanielleRioux, NathalieMunchhof, MichaelJin, LeiBoriak-Sjodin, P. AnnWigle, Tim J.Jacques, Suzanne L.West, Kip A.Lingaraj, TruptiStickland, KimberlyRibich, Scott A.Raimondi, AlejandraPorter-Scott, MargaretWaters, Nigel J.Pollock, Roy M.Smith, Jesse J.Barbash, OlenaKruger, Ryan G.Copeland, Robert A.Moyer, Mikel P.Chesworth, RichardDuncan, Kenneth W.
- [2] JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models[J]. CANCER RESEARCH, 2018, 78 (13)Wu, TongfeiMillar, HillaryGaffney, DanaBeke, LijsMannens, GeertVinken, PetraSommers, IvanThuring, Jan-WillemSun, WeimeiMoy, ChristopherPande, VineetZhou, JunguoHaddish-Berhane, NahorSalvati, MarkLaquerre, SylvieLorenzi, Matthew V.Brehmer, Dirk
- [3] Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models[J]. CANCER RESEARCH, 2020, 80 (16)Bhagwat, NehaZhang, YangLin, HongWang, MinRominger, DaveEmm, TomChugani-Mahtani, DivyaAngelis, DimitriosShetty, RupaLeal, RaulGowen-MacDonald, WilliamGrego, AlexanderLuengo, JuanManshouri, TaghiPastore, FriederikeLevine, Ross L.Verstovsek, SrdanRuggeri, BruceScherle, PeggyVaddi, Kris
- [4] A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models[J]. NATURE CHEMICAL BIOLOGY, 2015, 11 (06) : 432 - +Chan-Penebre, ElayneKuplast, Kristy G.Majer, Christina R.Boriack-Sjodin, P. AnnWigle, Tim J.Johnston, L. DanielleRioux, NathalieMunchhof, Michael J.Jin, LeiJacques, Suzanne L.West, Kip A.Lingaraj, TruptiStickland, KimberlyRibich, Scott A.Raimondi, AlejandraScott, Margaret PorterWaters, Nigel J.Pollock, Roy M.Smith, Jesse J.Barbash, OlenaPappalardi, MelissaHo, Thau F.Nurse, KelvinOza, Khyati P.Gallagher, Kathleen T.Kruger, RyanMoyer, Mikel P.Copeland, Robert A.Chesworth, RichardDuncan, Kenneth W.
- [5] A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models[J]. Nature Chemical Biology, 2015, 11 (6) : 432 - 437Chan-Penebre E.Kuplast K.G.Majer C.R.Boriack-Sjodin P.A.Wigle T.J.Johnston L.D.Rioux N.Munchhof M.J.Jin L.Jacques S.L.West K.A.Lingaraj T.Stickland K.Ribich S.A.Raimondi A.Scott M.P.Waters N.J.Pollock R.M.Smith J.J.Barbash O.Pappalardi M.Ho T.F.Nurse K.Oza K.P.Gallagher K.T.Kruger R.Moyer M.P.Copeland R.A.Chesworth R.Duncan K.W.
- [6] In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models[J]. CANCER RESEARCH, 2019, 79 (13)Millar, Hillary J.Brehmer, DirkVerhulst, TinneHaddish-Berhane, NahorGreway, TonyGaffney, DanaBoeckx, AnVan Heerde, ErikaNys, ThomasPortale, JosephPhilippar, UlrikeWu, TongfeiLaquerre, SylviePackman, Kathryn
- [7] Preclinical In vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models[J]. CANCER RESEARCH, 2018, 78 (13)Chikkanna, DineshPanigrahi, Sunil KumarRajagopalan, SujathaSammeta, Srinivasa RajuChawla, DarshanPavithra, S.Samiulla, D. S.Prasanna, AngeleneChand, PriyabrataAithal, KiranMarri, Sai SudheerKumar, NaveenGanipisetty, Srinivasa RaoMutyala, RajuRao, KasieswaraAntony, ThomasDaginakatte, GirishLakshminarasimhan, AnirudhaMohan, R.Narasihmarao, K.Chelur, ShekarPandit, ChetanSamajdar, SusantaRamachandra, Murali
- [8] LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 612 - 617Bonday, Zahid Q.Cortez, Guillermo S.Grogan, Michael J.Antonysamy, StephenWeichert, KenBocchinfuso, Wayne P.Li, FenglingKennedy, StevenLi, BinghuiMader, Mary M.Arrowsmith, Cheryl H.Brown, Peter J.Eram, Mohammad S.Szewczyk, Magdalena M.Barsyte-Lovejoy, DaliaVedadi, MasoudGuccione, ErnestoCampbell, Robert M.
- [9] Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer[J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)Liu, ShuangjieLiu, ZhuonanPiao, ChiyuanZhang, ZheKong, ChuizeYin, LeiLiu, Xi
- [10] Discovery of PF-06855800, a SAM competitive PRMT5 inhibitor with potent antitumor activity[J]. CANCER RESEARCH, 2018, 78 (13)Mcalpine, Indrawan J.Tatlock, JohnBillitti, JosephBraganza, JohnBrooun, AlexeiDeng Ya-LiHirakawa, BradJensen-Pergakes, KristenKumpf, RobertLiu, WeiMaegley, KarenMcTigue, MichelePatman, RyanRui, EugeneScales, StephanieSpiegel, NoahTran-Dube, MichelleWang, FenWang, ZhenxiongYamazaki, ShinjiZhang, TaoWythes, Martin